# US 2019/0375832 A1 · Garp-tgf-beta 1 antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375832 A1
- Document ID: US20190375832A1
- Status: Published application
- Kind: A1
- Application number: 16/409,679
- Filed: 2019-05-10
- Published: 2019-12-12
- Earliest claimed: 2017-05-11
- Assignees: argenx BVBA; Université Catholique De Louvain
- Applicants: argenx BVBA; Université Catholique de Louvain
- Inventors: Sebastian van der Woning; Filip Borgions; Torsten Dreier; Lore Mariën; Gitte De Boeck; Stéphanie Liénart; Sophie Lucas; Pierre Coulie
- Web page: https://patentgrep.com/patent/US20190375832A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 2039/505: {comprising antibodies}
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/32: specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/526: CH3 domain
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-β1, particularly a complex of human GARP and human TGF-β1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-β from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.

## Claims

### Claim at position 1

1-30. (canceled)

### Claim 31

A nucleic acid encoding a recombinant antibody or antigen binding fragment thereof, which binds to a complex of human glycoprotein A repetitions predominant (GARP) and TGF-β1, wherein the antibody or antigen binding fragment thereof comprises
a heavy chain variable domain (VH), wherein:
the VH CDR3 comprises the amino acid sequence YEWETVVVGDLMYEYEY (SEQ ID NO:13),
the VH CDR2 comprises the amino acid sequence RIDPEDAGTKYAQKFQG (SEQ ID NO:12), and
the VH CDR1 comprises the amino acid sequence SYYID (SEQ ID NO:4); and a light chain variable domain (VL), wherein:
the VL CDR3 comprises the amino acid sequence QQYASVPVT (SEQ ID NO:11),
the VL CDR2 comprises the amino acid sequence GASRLKT (SEQ ID NO:10), and
the VL CDR1 comprises the amino acid sequence QASQSISSYLA (SEQ ID NO:9).

### Claim 32 (depends on 31)

The nucleic acid of claim 31, wherein antibody or antigen binding fragment comprises a VH comprising the amino acid sequence of SEQ ID NO:14 and a VL comprising the amino acid sequence of SEQ ID NO:15.

### Claim 33 (depends on 32)

The nucleic acid of claim 32, which comprises the sequences of SEQ ID NO:18 and SEQ ID NO:19.

### Claim 34 (depends on 32)

The nucleic acid of claim 32, wherein the antibody or antigen binding fragment further comprises a CH1 domain, hinge region, CH2 domain and/or CH3 domain of a human IgG.

### Claim 35 (depends on 34)

The nucleic acid of claim 34, wherein the human IgG is IgG1.

### Claim 36 (depends on 34)

The nucleic acid of claim 34, wherein the human IgG is IgG4.

### Claim 37 (depends on 36)

The nucleic acid of claim 36, wherein the human IgG4 has the substitution S228P in the CH3 domain.

### Claim 38 (depends on 31)

The nucleic acid of claim 31, wherein antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:16 and a light chain comprising the amino acid sequence of SEQ ID NO:17.

### Claim 39 (depends on 38)

The nucleic acid of claim 38, which comprises the sequences of SEQ ID NO:20 and SEQ ID NO:21.

### Claim 40 (depends on 31)

An expression vector comprising the nucleic acid of claim 31 operably linked to regulatory sequences which permit expression of an antibody, antigen binding fragment, heavy chain variable domain, or light chain variable domain in a host cell or cell-free expression system.

### Claim 41 (depends on 40)

A host cell or cell-free expression system containing the expression vector of claim 40.

### Claim 42 (depends on 41)

A method of producing a recombinant antibody or antigen binding fragment thereof, comprising culturing the host cell or cell-free expression system of claim 41 under conditions which permit expression of the antibody or antigen binding fragment; and recovering the expressed antibody or antigen binding fragment.

### Claim 43 (depends on 32)

An expression vector comprising the nucleic acid of claim 32 operably linked to regulatory sequences which permit expression of an antibody, antigen binding fragment, heavy chain variable domain, or light chain variable domain in a host cell or cell-free expression system.

### Claim 44 (depends on 43)

A host cell or cell-free expression system containing the expression vector of claim 43.

### Claim 45 (depends on 44)

A method of producing a recombinant antibody or antigen binding fragment thereof, comprising culturing the host cell or cell-free expression system of claim 44 under conditions which permit expression of the antibody or antigen binding fragment; and recovering the expressed antibody or antigen binding fragment.

### Claim 46 (depends on 38)

An expression vector comprising the nucleic acid of claim 38 operably linked to regulatory sequences which permit expression of an antibody in a host cell or cell-free expression system.

### Claim 47 (depends on 46)

A host cell or cell-free expression system containing the expression vector of claim 46.

### Claim 48 (depends on 47)

A method of producing a recombinant antibody, comprising culturing the host cell or cell-free expression system of claim 47 under conditions which permit expression of the antibody; and
recovering the expressed antibody.
